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Abstract 
Background 
Despite high rates of disease misclassification and sepsis, the use of transrectal biopsy 
remains commonplace.  Transperineal mapping biopsies mitigate these problems but carry 
increased cost and patient burden.  Local anaesthetic (LA), multiparametric MRI (mpMRI)-
targeted transperineal biopsy may offer an alternative. 
Objective 
The objective was to determine the feasibility and tolerability of using a novel LA 
transperineal visually estimated prostate biopsy technique. 
Design, Setting, and Participants 
Consecutive men whose pre-biopsy mpMRI showed a visible lesion and underwent LA 
transperineal targeted prostate biopsy were included.  Pathology and mpMRI data was 
collected.   
Intervention 
Biopsies were performed in a visually estimated manner, using both mpMRI images and 
pictorial radiology reports.  LA was administered to the rectum, perineal skin and by peri-
prostatic block.  
Outcome Measurements and Statistical Analysis 
Primary outcomes were detection of significant cancer, adverse events and visual analogue 
scale (VAS) pain scores.  Significant cancer was defined by UCL definitions one and two and 
by the presence of Gleason 4 disease.  Secondary outcomes were detection of any cancer, 
detection by Likert score and by presenting PSA.  Differences were assessed using Chi-
squared tests (p < 0.05). 
Results and Limitation 
216 men with 284 lesions were included.   There were no episodes of sepsis or 
readmissions.  Median VAS score was 1.6.  116/216 (54%) had UCL definition 1 disease, 
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155/216 (72%) had UCL definition 2 cancer.  Any cancer was detected in 168/216 (78%).  
Significant disease was more likely in higher scoring lesions and in men with PSAs ≥10ng/mL.  
Conclusions  
This approach to prostate biopsy is feasible, tolerable and can be performed in ambulatory 
settings.  
Patient Summary 
This study looked at whether a prostate biopsy technique under local anaesthetic could 
improve existing prostate cancer pathways.  The procedure has excellent cancer detection 
rates, minimal side effects and is well tolerated, thus could represent an alternative to 
traditional transrectal biopsies. 
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Text 
Introduction 
The transrectal ultrasound (TRUS) guided prostate biopsy led diagnostic pathway remains 
commonplace.  However, this leads to misclassification of disease in men at risk of prostate 
cancer1.  Under-sampling of the anterior gland and the deployment of the needle blind to 
the location of the lesion can potentially miss clinically significant disease whilst also failing 
to directly hit the highest grade disease1.  Additionally, this pathway can also result in 
overdiagnosis and overtreatment2.  The primary issue is the limited ability of this pathway to 
discriminate between whether cancer is present and whether it is clinically significant or 
insignificant.  Furthermore, there is a significant risk of systemic sepsis following TRUS 
biopsy and this is increasing alongside a rise in antimicrobial resistant coliforms3.  Despite 
this, the TRUS biopsy still remains the first line diagnostic test in prostate cancer4.  
The diagnostic pathway requires improvement. Two separate diagnostic innovations may 
address the need for improved accuracy and safety. First, the implementation of a pre-
biopsy multi-parametric MRI can facilitate targeted sampling of a suspicious area with the 
potential of reduced number of cores whilst improving the detection rates of significant 
disease5.  Targeted biopsies may be equally good as a template approach in detecting 
clinically significant disease6. Second, the prostate may be approached transperineally 
rather than via the rectum, easing access to all areas of the prostate, and conferring sepsis 
rates of less than 0.5%7.  Transperineal biopsies are often applied in a mapping technique, 
sampling the whole-gland with a fixed sampling frame of 5-10mm.  This method has 
demonstrable diagnostic accuracy when compared to the reference standard of radical 
prostatectomy8. However, barriers to widespread adoption include the necessity of general 
or spinal anaesthetic; operating room time; pathology resources/costs and increased risks of 
urinary retention, haematuria, haematospermia and temporary erectile dysfunction. 
Despite this, the approach has gained considerable momentum in the last decade. 
Nonetheless, reductions to these burdens are needed in order to facilitate widespread 
dissemination of a transperineal approach to prostate biopsy, capitalising on reduced sepsis 
rates. 
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The optimal biopsy strategy is likely to have the following elements. Firstly, it should be 
mpMRI led and suspicious areas undergo a targeted biopsy. Secondly, a transperineal 
approach should be used to capitalise on significantly reduced sepsis rates and improved 
gland sampling. Lastly, these biopsies should be conducted under local anaesthetic. In this 
study, our objective was to determine the feasibility, patient acceptability, pain scores, 
adverse events and estimates of cancer detection using such a pathway.  
 
Methods 
In this prospective study, which was part of a clinical service innovation approved by the 
institution and receiving research ethics committee exemption, consecutive men whose pre-
biopsy mpMRI showed a visible lesion and underwent a local anaesthetic transperineal 
targeted prostate biopsy were included.  
MpMRI acquisition was performed according to the European guidelines of Uro-radiology 
previously described by the UCL group5, 6, 9.  Each scan was reported by an experienced, uro-
radiologist as previously described 10.  Lesions were scored using a Likert-like scale of 1-511.  
Lesions scoring 3 (figure 1) were indeterminate, and those scoring 4 (figure 2) or 5 (figure 3) 
were thought ‘likely’ or ‘highly likely’ to contain a malignant lesion which was either ≥0.2mL 
in volume and/or had high grade components within (Gleason ≥3+4)12.   
Biopsies were performed by twelve urologists experienced in transperineal mapping and 
transperineal cognitive biopsy.  All were performed in a non-operating theatre procedure 
room as ambulatory day cases, with one urologist and two nursing assistants.  
One hour prior to biopsy, men received oral analgesia (Tramadol 100mg) and topical 2% 
diltiazem ointment to relax the anal sphincter. They were placed in the lithotomy position 
and given a single dose of intramuscular antibiotics (gentamicin 80mg).  
The scrotum was supported with adhesive tape with the scrotal skin protected by non-
adhesive dressings. 20mL of lidocaine infused gel (Instillagel®) was inserted into the rectum 
and applied to the anus. After two minutes, a bi-planer 7.5MHz ultrasound transducer was 
inserted transrectally. The perineum was then cleaned with Chloraprep® and 20mL of 0.5% 
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bupivacaine with adrenaline (1 in 200,000) was infiltrated in the perineal skin just anterior 
to the anus as well as deep into sub-cutaneous tissue. After two minutes, a peri-prostatic 
block was performed transperineally by infiltration of the peri-prostatic nerves with 0.5% 
bupivacaine 10mL and 1% lidocaine 10mL (figure 4).  Finally, the probe was attached to a 
brachytherapy stepper and cradle.  Transperineal targeted biopsies were performed in a 
cognitive manner by evaluating the mpMRI images and a pictorial diagrammatic report 
provided by the uro-radiologist. 
In the first 14 patients, pain scores were collected to determine tolerability.  Adverse events 
were also evaluated along with baseline demographics, prostate volume, lesion size and 
number of biopsies taken.  Overall cancer detection rates were determined as was the rates 
of detection for measures of clinically significant disease using a number of thresholds. The 
definition of disease according to the UCL criteria for clinical significance developed for 
transperineal biopsies were used13. Definition 1 was the presence of Gleason ≥4+3 and/or 
maximum cancer core length ≥6mm and definition 2 was the presence of Gleason ≥3+4 
and/or maximum cancer core length ≥4mm. The detection rate of lesions containing 
Gleason pattern 4 alone regardless of cancer core length were considered separately. 
Epstein criteria were not used, as these have not been validated on targeted biopsies14.  
Differences in cancer detection rates by Likert score were compared for significance using 
the Chi-squared test (p<0.05).   
Additionally, the group was separated into men presenting with a PSA ≥10ng/mL and 
<10ng/mL.  Differences between these groups were evaluated for prostate volume 
(Student’s T-test [p<0.05]) and lesion volume (one-way analysis of variance (ANOVA 
[p<0.05]).  PSA dependent differences in the attributable Likert score on mpMRI were 
compared (Chi-squared test [p<0.05]).  Statistical analysis was conducted using SPSS version 
22 (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: 
IBM Corp). 
 
Results 
Baseline Demographics (Table 1a): 
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Between September 2013 and January 2016, 216 consecutive men with 284 lesions on 
mpMRI underwent targeted prostate biopsy under local anaesthetic.  Mean age at the time 
of biopsy was 68 (range 46 to 92).  183 biopsies were performed prior to any treatment with 
33 being performed afterwards. 
Median PSA was 9.4ng/mL (interquartile range [IQR] 5.9-23.0ng/mL).  Median prostate 
volume was 45mL (IQR 32-66mL).  Median target lesion volume was 0.5mL (IQR 0.2-2.0mL). 
163 men had a single targeted lesion, 39 had two, 13 had three and one had four.  Of the 
284 lesions targeted, 78 (27%) scored 3 on the radiological Likert-like scale, 107 (38%) 
scored 4 and 99 (35%) scored 5.  A median of five (IQR 4-6) cores were taken per lesion.  
 
Primary outcome 1 - Tolerability and adverse events 
There were no episodes of sepsis, none had bleeding requiring catheterisation and no 
catheter requirement post-biopsy.  There were no admissions following discharge.  The first 
14 men were assessed by the visual analogue scale for pain to assess for tolerability.   The 
median intraoperative score was 1.6 (range 0 to 7; IQR 0.8-2.6).  One procedure was 
abandoned due to patient discomfort. 
 
Primary outcome 2 – detection of clinically significant cancer 
On a patient level, 116/216 (54%) had UCL definition 1 disease and 155/216 (72%) had UCL 
definition 2 cancer. 150/216 (69%) had any Gleason pattern 4 or greater with 61/216 (28%) 
dominant pattern 4 or greater.  On a lesion basis, 127/284 (45%) had UCL definition 1 
disease and 184/284 (65%) had UCL definition 2 disease.  176/284 (62%) had any Gleason 
pattern 4 or greater with 64/284 (23%) dominant pattern 4 or greater. 
 
Secondary outcomes 
a) Overall cancer detection: Prostate cancer was detected in 168/216 (78%).  When 
analysed by lesion (table 2a), 210/284 (74%) had prostate cancer detected. Overall, the 
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median number of positive cores for each lesion was 2 (IQR 1-4).  The maximum cancer core 
length involvement was median 6mm (IQR 3mm to 10mm).   
 
b) Detection rates by radiology score 
Of the 78 lesions scoring 3 on mpMRI, 38 (49%) had cancer detected of whom 24 (63%) 
contained Gleason pattern 4 disease (table 2b).  Thirteen (54%) of these men reached 
criteria for UCL definition 1 for clinical significance and 24 (100%) met the criteria for UCL 
definition 2 disease.  Of the 107 lesions scoring 4 on mpMRI, cancer was detected in 78/107 
(73%) of which 65 (83%) contained Gleason pattern 4 or higher.  Forty (37%) reached UCL 
definition 1 for clinical significance and 70 (90%%) the criteria for UCL definition 2 disease.  
Finally, 99 lesions (35%) were scored 5 on mpMRI. Any cancer was detected in 94 (95%) of 
which 87 (88%) contained Gleason pattern 4 or higher.  Of these, 74 (75%) reached UCL 
definition 1 for clinical significance and 90 (96%) met the criteria for UCL definition 2 
disease.  In all scenarios, namely any cancer detected, UCL definition 1 and 2 and any 
Gleason 4 disease detected there was a statistically significant correlation with higher Likert 
scores (Chi-squared test, p < 0.00001). 
 
c) Cancer detection by PSA (Table 1b) 
102 men (47%) with 131 lesions (46%) had a PSA of ≥10ng/mL.  By comparison, 114 men 
(53%) with 153 lesions (54%) had a PSA <10ng/mL.   
Men with a PSA ≥10ng/mL had significantly larger prostates (Student’s T-test, p=0.002). Men 
presenting with a PSA ≥10ng/mL also had significantly larger lesions (one-way ANOVA, 
p=0.002). 
Of 153 mpMRI lesions identified in men with a PSA <10ng/mL, 52 (34%) were scored 3 on 
the Likert scale, 69 (45%) scored 4 and 32 (21%) scored 5.  Of 131 mpMRI lesions identified 
in men with a PSA ≥10ng/ml, 26 (18%) scored 3 on the Likert scale, 38 (29%) scored 4 and 67 
(51%) scored 5.  Men with higher PSA levels were more likely to have higher scoring lesions 
on mpMRI (Chi-squared, p<0.00001). 
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Clinically significant disease (UCL definitions 1 and 2) was found in 85 (59%) of lesions in 
men presenting with a PSA <10ng/mL and 99 (65%) of lesions in men presenting with a PSA 
≥10ng/mL.  These differences were statistically significant (Chi-squared, p=0.03). 
 
Discussion 
In summary, to the best of our knowledge this is the first time that local anaesthetic 
transperineal mpMRI-targeted prostate biopsy has been reported.  We have shown that this 
technique is feasible, acceptable and tolerable by patients, has very minimal adverse events 
and no sepsis.  It also seems to be highly accurate in detecting clinically significant cancer 
with 96% of men scoring 4 or 5 on mpMRI harbouring Gleason pattern 4 disease. 
 
Methodological limitations 
Before discussing the clinical implications of our results, we would like to highlight some 
limitations.  First, the analysis was retrospective with a heterogenous population including 
biopsy-naïve men and those undergoing risk stratification or post-treatment evaluation.  
Second, some argue that targeted biopsies alone without sampling of normal appearing 
gland on mpMRI risks missing significant disease.  Our change in strategy for this group of 
men occurred after our paired analyses of mpMRI versus transperineal template mapping 
biopsies in men demonstrated that mpMRI visually directed biopsies were equivalent in 
detection rate to full mapping biopsies when both were conducted in the same men under 
general anaesthetic15.  This has been supported by other studies with one recent study 
showing that only 4% of clinically significant disease would have been missed with a target 
alone strategy16.  Other authors have also demonstrated negative predictive values of 90% 
or higher17-19.  Third, consensus is lacking regarding the definition of clinically significant 
cancer.  Therefore, we used a number of definitions to incorporate professional uncertainty.  
Fourth, multiple radiologists and urologists were involved in the reporting of mpMRI scans 
and biopsies.  
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Clinical implications  
The diagnosis and subsequent management of prostate cancer is still driven by TRUS biopsy 
despite its accepted inaccuracy.  Indeed, the original six-core TRUS biopsy technique was 
described as random systematic by Stamey in 198920.  Subsequently, the procedure was 
expanded to a 10 to 12-core technique over time.  This was somewhat successful in 
increasing the negative predictive value of TRUS biopsy. However, it also led to the 
detection of increased numbers of low risk disease.  Histological studies have demonstrated 
this is present in more than 40% of men over the age of 5021.  Furthermore, the TRUS biopsy 
is poor at detecting disease in anterior and apical aspects of the gland leading to 
misclassification of disease that is upgraded at prostatectomy22.   
Due to these concerns, transperineal mapping biopsy is becoming more popular. However, 
concerns regarding its cost, the need for general anaesthetic and increased complications in 
the form of haematuria, haematospermia and urinary retention are likely to have prevented 
its wider dissemination. With the advent of mpMRI, which has shown high levels of accuracy 
for the detection of clinically significant cancer when compared to whole-mount histological 
specimens23 and transperineal mapping biopsies15, an image-guided approach to prostate 
biopsy in line with current practice in other solid organ malignancies can now be 
contemplated24.  A number of centres have reported their experiences with mpMRI-
targeted biopsy when compared to systematic biopsy strategies, demonstrating improved 
cancer detection rates5, 25, improvements in biopsy efficiency5 and reductions in missed 
diagnoses of significant cancer26. 
Additionally, some centres have described their use of transperineal biopsy (non-targeted) 
under local anaesthetic with encouraging results27-30.  Novella et al compared the procedure 
to 102 consecutive patients27.  Only 11 (15.3%) reported intraoperative pain levels of 
moderate or higher27.  Kubo et al compared intraoperative pain levels in 45 patients who 
underwent both 12-core TRUS biopsy and 14-core transperineal biopsy solely under local 
anaesthetic28.  The median VAS score was 2.67 for TRUS and 2.93 for transperineal biopsy 
with no significant difference demonstrated28.  Iremashvili et al reported a randomised 
clinical trial where 150 patients underwent 12-core transperineal prostate biopsy under 
local anaesthesia, some with a pudendal nerve block29.  Those who received a pudendal 
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nerve block did experience less intraoperative pain at a median of 1.83 on VAS29.  However, 
even without this the median VAS suggested mild intraoperative pain levels at a median of 
2.4129.  Most recently, Smith et al described a series of 50 consecutive patients that 
underwent sector transperineal biopsies solely under local anaesthetic30.  Only 2 (4%) of 
men reported that they would not undergo the same procedure again30. 
Whilst the use of transperineal template mapping biopsies has shown a significant growth in 
use due to its highly accurate detection and risk stratification of disease, it has met with 
criticism due to its healthcare and patient burden.  For the one million men who have a 
TRUS biopsy in the USA or Europe each year to undergo template mapping biopsies would 
be unsustainable.  MpMRI has shown performance characteristics in high volume 
experienced centres that make it a viable alternative to TRUS and template biopsies. As a 
result, many centres have adopted mpMRI-targeted biopsies. However, much of this still 
relies on traversing the rectum.  Our strategy to combine the key elements of an optimal 
diagnostic pathway may facilitate the wider adoption of transperineal prostate biopsy which 
is known to have minimal risk of sepsis whilst retaining diagnostic accuracy. 
 
Conclusion 
Local anaesthetic, transperineal visual estimated targeted mpMRI-targeted prostate biopsy 
is a novel approach that is feasible, tolerable and can be performed in an ambulatory 
setting. It carries high levels of cancer detection and may offer a sustainable and legitimate 
alternative to transrectal biopsies.    
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Figure and Table legends 
Figure 1: MpMRI images (T2, ADC, and DCE) of a Likert 3 lesion. 
Figure 2: MpMRI images (T2, ADC, and DCE) of a Likert 4 lesion. 
Figure 3: MpMRI images (T2, ADC, and DCE) of a Likert 5 lesion. 
Figure 4: Diagram of the application of local anaesthetic. 
Table 1: Baseline demographics for the whole cohort and as separated by PSA. 
Table 2: Cancer detection in men and by mpMRI lesion. 
